CORT: FDA Letter Sparks 50% Drop—Is it Time to Buy?

Overview and Stock Plunge

Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage pharmaceutical company focused on developing drugs that modulate the hormone cortisol. The company’s only marketed drug is Korlym® (mifepristone), approved in 2012 for treating endogenous Cushing’s syndrome (hypercortisolism) ([1]). In late 2025, Corcept’s shares were rocked by a major regulatory setback: the FDA issued a Complete Response Letter (CRL) rejecting Corcept’s New Drug Application (NDA) for relacorilant (a selective cortisol modulator) as a treatment for hypertension caused by Cushing’s syndrome ([2]). The FDA concluded it could not yet find a favorable benefit-risk profile for relacorilant without additional evidence of effectiveness ([2]). This surprise rejection on December 31, 2025 triggered a frenzied sell-off, with CORT stock plunging about 50% to ~$34.80 per share at the close ([3]). The pivotal question for investors is whether this sell-off has created a buying opportunity or if more pain lies ahead.

FDA’s CRL and Pipeline Outlook

The FDA’s letter acknowledged that Corcept’s pivotal GRACE trial did meet its primary endpoint for relacorilant and that a second study (GRADIENT) provided supporting evidence ([2]). However, the agency is requiring “additional evidence of effectiveness” before approval ([2]). In practice, analysts interpret this as a need for at least one new clinical trial, likely delaying relacorilant’s potential approval by several years. H.C. Wainwright, for example, now expects relacorilant’s launch for Cushing’s to be pushed out by about 3 years (to 2029) due to the additional data requirements ([4]). Truist Securities voiced similar concern, noting that new trial(s) would “significantly dim” relacorilant’s outlook in Cushing’s syndrome ([3]). Corcept’s CEO expressed confidence in finding a path forward and plans to meet with the FDA promptly ([2]), but there is no guarantee relacorilant will succeed in this indication without substantial new evidence.

Importantly, the setback in Cushing’s does not derail Corcept’s other relacorilant program in oncology. The company has a separate NDA under FDA review for relacorilant in platinum-resistant ovarian cancer, with a Prescription Drug User Fee Act (PDUFA) decision date set for July 11, 2026 ([2]). Analysts note that the Cushing’s CRL has no bearing on the ovarian cancer review ([3]). The ovarian indication showed positive Phase 3 results (the ROSELLA trial met its primary endpoint) and could become an important value driver if approved ([5]). Corcept has also submitted a Marketing Authorization Application in Europe for relacorilant in ovarian cancer ([2]). Thus, while the Cushing’s setback is significant, the relacorilant story isn’t over – one major FDA decision (for ovarian cancer) still lies ahead in 2026.

Core Business: Korlym Drives Revenue and Growth

Despite the high-profile pipeline disappointment, Corcept’s core business – Korlym for Cushing’s syndrome – remains intact and has been delivering robust growth. Corcept is essentially a one-product company today, with Korlym (and its authorized generic) generating all its revenue ([1]) ([4]). Demand for Cushing’s treatments has been rising as physicians better recognize and screen for hypercortisolism’s true prevalence. In 2024, Corcept’s revenue reached $675.0 million, up 40% year-over-year, with net income of $141.2 million (diluted EPS of $1.23) ([6]). This reflects strong uptake of Korlym – the company reported record numbers of patients on treatment and new prescribers in 2024 ([6]). Growth continued into 2025: second-quarter 2025 revenue was $194.4 million (vs. $163.8M in the year-ago quarter) with $35.1M in net income ([5]). Management had initially guided 2025 revenues to $900–950 million ([6]). However, supply-chain bottlenecks at its specialty pharmacy partner led to a temporary fulfillment shortfall, and full-year guidance was later trimmed to about $800–850 million ([7]). Even at the low end, that implies ~18% growth over 2024’s sales – a solid trajectory. Notably, Corcept’s Cushing’s franchise has remained profitable, with quarterly earnings generally in the black. For example, in Q3 2025 Corcept earned $0.16 GAAP EPS even after revenue came in lighter than expected ([7]) ([7]). This profitability distinguishes Corcept from many small biotechs and provides internal funding for R&D and shareholder returns.

Dividend Policy and Shareholder Returns

Corcept does not pay a dividend, and it has never declared any cash dividends to shareholders (current dividend yield = 0%) ([1]). Instead, the company has elected to return capital via stock buybacks. In January 2024, Corcept’s board authorized a $200 million share repurchase program ([8]). Under this program, the company repurchased $38.0 million of its stock during 2024 ([6]), and accelerated purchases in 2025 – buying back $115.4 million worth of shares in just the second quarter of 2025 ([5]). These buybacks reflect management’s confidence in the business and helped reduce the outstanding share count modestly (supporting earnings per share). While no dividend income is on offer, these repurchases have been a way to return value to shareholders and signal optimism from the company. Given the recent price plunge, investors will be watching to see if Corcept steps up buybacks again at the now-depressed share price (subject to remaining authorization and cash needs).

Financial Position and Leverage

Corcept’s balance sheet appears strong and conservatively financed, which is crucial after an unexpected setback. The company held $603.2 million in cash and marketable investments as of December 31, 2024 ([6]). Even after significant buyback spending, cash was still about $515 million mid-2025 ([5]). Importantly, Corcept carries almost no debt – its long-term debt was reported as $0 in recent years ([9]). The debt-to-equity ratio is essentially 0% ([10]), and Corcept has more cash on hand than total liabilities. This lack of leverage means there are no near-term debt maturities or interest burdens to worry about. In fact, the company likely earns interest income on its cash (given rising rates) rather than paying interest expense. High financial liquidity gives Corcept the flexibility to weather storms (such as a delayed product launch) and to fund ongoing R&D or possible new trials without immediately needing to raise capital. In short, balance sheet risk is low – an attractive feature for a small biotech. The ample cash also provides optionality: Corcept could invest in developing its pipeline, consider strategic acquisitions/licensing, or continue shareholder buybacks as circumstances warrant.

Valuation and Market Sentiment

Prior to the FDA letter, Corcept’s stock had performed strongly, reflecting high expectations for relacorilant and the growth of Korlym. The collapse in share price has sharply reduced Corcept’s valuation multiples. At around $35 per share (post-drop), CORT trades at roughly 28× trailing earnings (EPS ~$1.23 ([6])) and about 5× forward sales (using ~$825M 2025 revenue guidance). This is a far cry from the double-digit price/sales and much higher P/E it sported before. The question is whether the current valuation appropriately discounts the risks or instead underestimates the company’s resilience. Notably, Wall Street analysts largely remain bullish despite the setback. For example, Canaccord Genuity kept a Buy rating on CORT and only trimmed its price target from $140 to $99, arguing that the sell-off is a buying opportunity given Korlym’s continuing growth and the limited near-term impact of generics ([4]) ([4]). H.C. Wainwright also reiterated a Buy, cutting its target from $145 to $90, and noted that the FDA’s CRL likely just delays relacorilant’s launch by ~3 years but does not diminish Corcept’s longer-term prospects ([4]). Even Truist, which drastically slashed its target from $135 to $50 after the news, set that new target above the current trading level ([3]). In sum, the stock is now priced more like a steady single-product biotech with an uncertain pipeline, whereas before it was priced for significant near-term pipeline success. If Korlym’s cash flows remain durable (see Risks below) and if the ovarian cancer indication (or other pipeline assets) pan out, the current valuation could prove attractive. Conversely, if further negatives materialize, the seemingly “cheap” multiples could prove to be a value trap. Investor sentiment will likely hinge on upcoming catalysts and how the risks are navigated.

Key Risks and Red Flags

Several risks and potential red flags should be considered before jumping into CORT stock, even at depressed prices:

– Generic Competition for Korlym: Corcept’s dominance in the Cushing’s syndrome market faces a looming patent cliff. In late 2023, a U.S. district court ruled in favor of Teva in Corcept’s patent lawsuit, undermining certain Korlym patents ([11]). Teva’s generic mifepristone (Korlym) ANDA had already been FDA-approved in 2020 ([11]), and Teva could launch at risk once legal stays expire. Corcept is appealing the decision ([12]), but if the appeal fails, a generic Korlym could hit the market much earlier than expected, eroding Corcept’s chief revenue source. (Corcept previously settled with other generic filers like Sun and Hikma, allowing generic entry in 2034 ([13]) ([14]), but Teva has not settled.) An early generic entry would likely cause Korlym sales – and Corcept’s margins – to decline precipitously. This patent litigation outcome remains a huge swing factor for the stock.

– Reliance on One Product: Korlym (mifepristone) accounts for essentially all of Corcept’s revenues ([1]). This concentration means any issue with Korlym could severely impact the company. Beyond generics, Korlym could face commercial competition from new Cushing’s therapies. Recordati’s Isturisa® (osilodrostat) and Xeris’s Recorlev® (levoketoconazole) were approved in 2020–2021 and target the same patient population ([15]) ([15]). Novartis’s Signifor® (pasireotide) is another approved therapy for Cushing’s ([15]). While Korlym remains the only marketed cortisol receptor blocker and has grown with the market, increased physician adoption of these alternatives or new treatments could slow Korlym’s growth. Any safety concerns or new contraindications for Korlym (or mifepristone usage) would also be highly detrimental given the lack of diversification. Corcept is essentially all-in on cortisol modulation, which magnifies both its opportunity and its risk.

– Regulatory and Pipeline Risk: The FDA’s unexpected denial of relacorilant in Cushing’s underscores the unpredictability of drug approvals. Corcept spent years and significant R&D on that program – yet one of its Phase 3 trials failed to beat placebo ([3]), ultimately leading to the FDA demanding more data. There is a risk that even after additional trials, relacorilant might not demonstrate enough benefit in Cushing’s to merit approval. Likewise, other pipeline candidates carry typical developmental risks: for example, Corcept’s next prominent program is relacorilant in ovarian cancer (FDA decision mid-2026). While Phase 3 results were positive, the regulatory outcome isn’t guaranteed, and even with approval, uptake in oncology settings is uncertain. Corcept is also investigating dazucorilant (a separate cortisol modulator) in disorders like ALS and liver disease, and miricorilant for metabolic conditions ([8]), among others – but these are early-stage and not assured successes. Setbacks in any of these could hurt future growth prospects. The company’s strategy of expanding cortisol modulation to new disorders is promising but unproven at commercial scale beyond Cushing’s.

– Financial Constraints and Execution: Although Corcept is currently profitable and cash-rich, a prolonged delay in relacorilant’s approval (or a hit to Korlym sales) could strain its finances over time. The company’s operating expenses have been rising (Q2 2025 OpEx jumped to $167.8M from $128.2M a year prior) as it supports multiple clinical programs ([5]). If revenue growth stalls or contracts (e.g. due to generics or competition), Corcept may need to make tough choices on R&D spending, potentially slowing its pipeline progress. Thus far management has executed well on growing Korlym, but execution risks remain – for instance, the specialty pharmacy distribution snafu in 2025 revealed an operational hiccup that temporarily constrained sales ([7]). Any further missteps in supply chain, compliance, or commercialization could pose challenges for a relatively small company scaling up its product portfolio.

– Legal and Shareholder Scrutiny: Large stock drops often attract shareholder lawsuits. Indeed, at least one law firm has announced an investigation into whether Corcept misrepresented anything related to the relacorilant trials or prospects before the CRL ([16]). Such class-action lawsuits are not uncommon after biotech surprises, and while often not meritorious, they can distract management and incur legal costs. Additionally, Corcept’s aggressive patent tactics (filing numerous follow-on patents to extend Korlym’s exclusivity ([17]) ([17])) drew criticism from a judge and could be seen as a red flag about corporate governance or strategy. Investors should monitor any developments on these fronts. There has also been insider selling in 2025 when CORT stock was near highs (e.g. sales by executives/directors around $60–$75/share in late 2025) ([18]), which, while often pre-planned, is worth noting.

In sum, Corcept faces a convergence of risks: an impending patent expiry battle, dependence on a niche market drug, and the uncertainties of drug development. These are significant caveats to the bull thesis.

Outlook and Open Questions – Is CORT a Buy Now?

The 50% crash in CORT has undoubtedly made the stock “cheaper” by conventional metrics, but whether it is a compelling buy hinges on how the above risks and variables play out. Investors considering Corcept now should be asking a few key questions:

– How secure are Korlym’s cash flows through the decade? The bull case assumes Korlym’s franchise can continue growing and remain essentially monopoly until 2034 (when settlements allow generic entry) ([13]) ([14]). However, the Teva situation creates uncertainty much sooner. If Corcept manages to fend off Teva’s generic (via appeal or settlement) and maintain exclusivity, Korlym could generate hundreds of millions in annual cash flow for years to fund R&D and buybacks. If a generic launches in the next 1–2 years, though, Corcept’s revenue and profit could fall off sharply. Clarity on the appeal outcome (or any settlement) will be crucial in 2024–2025.

– What is the path forward for relacorilant in Cushing’s? Management’s reaction to the CRL – whether they will run new Phase 3 trial(s), and if so, what endpoints or patient population to target – will determine if this program can be resurrected. Any new trials mean significant spending and at least a few years of wait. Investors will want to know the FDA’s feedback when Corcept meets with the agency. A key open question is whether a feasible shortcut exists (for example, using existing data or real-world evidence) or if a full new trial is needed. The timeline for relacorilant’s possible approval (late 2020s now, by analyst estimates ([4])) is far-off, diminishing its present value in the stock. How Corcept reallocates its resources in light of this delay – perhaps more emphasis on other programs – will be telling.

– Will the ovarian cancer indication deliver? The next major catalyst is the FDA’s decision on relacorilant for platinum-resistant ovarian cancer by July 11, 2026 ([2]). This represents a completely new market for Corcept. Approval could not only validate Corcept’s cortisol modulation approach in oncology but also open a revenue stream beyond Cushing’s. However, questions remain on the commercial side – e.g. how readily oncologists will adopt relacorilant (to be used with chemotherapy), what the competitive landscape is (there are many treatments in oncology), and pricing/reimbursement in this indication. Positive approval and launch in ovarian cancer would diversify Corcept’s business and could boost investor confidence, whereas a rejection or lackluster uptake would increase reliance on Korlym. European approval (now under EMA review ([2])) is another factor, though the U.S. decision is primary.

– Can Corcept’s other pipeline candidates advance successfully? Corcept has several earlier-stage programs, such as miricorilant for metabolic diseases (like NASH) and dazucorilant for ALS. Notably, an interim analysis of dazucorilant in ALS reportedly showed a reduction in early mortality ([5]), which is intriguing. The company will need to decide how aggressively to push these programs forward. Successful development of a second or third product (beyond Korlym/relacorilant) could transform Corcept into a multi-product company and reduce its reliance on Korlym. On the flip side, pursuing too many programs could burn cash quickly. The strategic focus and execution of R&D in the next couple of years will heavily influence Corcept’s long-term value. Investors should watch for clinical readouts (e.g. final ALS trial results expected by end of 2024 ([5])) and any partnerships or collaborations that might de-risk these programs.

– How will management deploy capital after the drop? With over $500M in cash, Corcept has options. Will it accelerate share repurchases given the stock’s decline (as a show of confidence)? Or will it conserve cash to invest in pipeline trials and potential in-licensing deals to bolster its portfolio? The answer will indicate management’s priorities. Additionally, any shift in 2026 guidance or cost structure (for example, trimming expenses to account for the relacorilant delay) will be informative. The company’s capital allocation between rewarding shareholders and investing for growth is a delicate balance, especially under new circumstances.

At the current juncture, Corcept Therapeutics offers a mix of high reward and high risk. On one hand, the core Cushing’s business is profitable, growing, and (for now) protected by patents and settlements, providing a strong foundation. The stock’s valuation has corrected to more reasonable levels that arguably don’t price in any major pipeline success. On the other hand, the overhang of patent litigation and the need to regenerate its pipeline prospects could cap the stock’s near-term upside until there is more clarity. For investors with a long-term horizon and tolerance for regulatory risk, CORT’s post-CRL slump could indeed represent an attractive entry – essentially buying a rare-disease cash cow with pipeline lottery tickets at a discount. However, more risk-averse investors may prefer to wait and see how the patent appeal and the ovarian cancer FDA decision play out in 2026, as these events will significantly influence Corcept’s trajectory.

Bottom Line: The FDA’s letter was a harsh blow that cut CORT in half, but it did not change the strengths of the existing Korlym franchise. With no debt, a war chest of cash, and an ongoing growth business, Corcept is fundamentally equipped to regroup. Whether it is “time to buy” depends on one’s conviction in Corcept’s ability to navigate the challenges ahead. A potential strategy for interested investors could be a tiered approach – initiating a position recognizing the company’s solid base, while keeping some buying power in reserve to either add on further dips or on confirmation of positive catalysts (like a favorable legal resolution or new drug approval). In the end, CORT presents a classic biotech conundrum: significant downside risks persist, but the upside in a recovery scenario (successful defense of Korlym + pipeline wins) could be substantial. As always, prudent position sizing and diligent monitoring of news will be key when investing in a story like Corcept at this critical inflection point.

＊＊＊

Sources: Corcept Therapeutics SEC filings, investor presentations and press releases; FDA and company announcements; Reuters ([11]), Business Wire ([2]) ([2]), BioSpace ([3]) ([3]), Insider Monkey/FinViz ([4]) ([4]), MacroTrends ([1]) ([1]), and other financial media reports. All financial figures are in USD.

Sources

1. https://macrotrends.net/stocks/charts/CORT/corcept-therapeutics/dividend-yield-history
2. https://biospace.com/press-releases/corcept-receives-complete-response-letter-for-relacorilant-as-a-treatment-for-patients-with-hypercortisolism
3. https://biospace.com/fda/fda-rejects-corcept-and-outlook-filings-crushing-stock-prices/
4. https://finviz.com/news/271664/price-targets-lowered-on-corcept-therapeutics-cort-after-fda-letter
5. https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announces-second-quarter-financial-3/
6. https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-announces-fourth-quarter-and-full-year-2024
7. https://indexbox.io/blog/corcept-therapeutics-q3-2025-results-revenue-misses-estimates-profit-beats/
8. https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-provides-financial-update-and-announces/
9. https://macrotrends.net/stocks/charts/CORT/corcept-therapeutics/long-term-debt
10. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/health
11. https://pharmalive.com/corcept-loses-patent-spat-against-teva-shares-tumble/
12. https://lifesciencesipreview.com/americas/corcept-to-vigorously-appeal-teva-victory-over-cushing-s-syndrome-drug-patents-5333
13. https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-settles-patent-litigation-sun
14. https://ir.corcept.com/news-releases/news-release-details/corcept-therapeutics-settles-patent-litigation-hikma/
15. https://sec.gov/Archives/edgar/data/1088856/000162828025008167/cort-20241231.htm
16. https://prnewswire.com/news-releases/corcept-therapeutics-cort-faces-investor-scrutiny-amid-receipt-of-fda-complete-response-letter-for-relacorilant-shares-tank-50–hagens-berman-302653971.html
17. https://markmanadvisors.com/blog/2023/5/9/why-did-corcepts-piecemeal-litigation-tactics-for-korlym-finally-backfire
18. https://insidertrades.com/alerts/nasdaq-cort-insider-buying-and-selling-2025-10-16/

For informational purposes only; not investment advice.